Evidence map›Paper›PMID 29708005›Full record

ReviewJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2018

MicroRNA-based therapeutics in central nervous system injuries.

Ping Sun, Da Zhi Liu, Glen C Jickling, Frank R Sharp, Ke-Jie Yin

Abstract readReview
In one paragraph

Review in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

135 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. MicroRNA-126 as an endogenous molecule for hypoxic/ischemic tolerance in neuroprotection.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  11. NamiRNA-Enhancer Network: The Changing Era Challenge and Chance of miRNA.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  12. Observational
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Causal role of MiRNAs in chronic rhinosinusitis: mendelian randomization and validation study.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025
    Article
  19. Review
  20. Review

75 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ping Sun1 Department of Neurology, Pittsburgh Institute of Brain Disorders & Recovery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Da Zhi Liu2 Department of Neurology and the M.I.N.D. Institute, University of California at Davis, Sacramento, CA, USA.
Glen C Jickling3 Department of Neurology, University of Alberta, Edmonton, Alberta, Canada.
Frank R Sharp2 Department of Neurology and the M.I.N.D. Institute, University of California at Davis, Sacramento, CA, USA.
Ke-Jie Yin1 Department of Neurology, Pittsburgh Institute of Brain Disorders & Recovery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Funding

Molecular Biology of Stroke in HumansR01NS075035 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SHARP, FRANK R · 2012 to 2016
$3.1M
Genomics of Intracerebral Hemorrhage and its CausesR01NS106950 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ANDER, BRADLEY PEARCE, SHARP, FRANK R · 2019 to 2023
$3.0M
Whole Genome RNA Sequencing (RNAseq) of Blood from Patients with Lacunar StrokeR01NS101718 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SHARP, FRANK R, STAMOVA, BORYANA · 2017 to 2021
$3.0M
Whole Transcriptome Studies of Patients with Transient Ischemic Attacks (TIAs)R01NS097000 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SHARP, FRANK R, STAMOVA, BORYANA · 2016 to 2020
$2.8M
A Novel Approach to Assessing Cryptogenic StrokeR01NS079153 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SHARP, FRANK R · 2012 to 2016
$2.8M
MicroRNAs and post-stroke angiogenesisR01NS091175 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHEN, JUN, YIN, KEJIE · 2015 to 2019
$2.5M
Role of the Src Family Kinases in Traumatic Brain InjuryR01NS089901 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LIU, DA ZHI · 2015 to 2019
$1.7M
Kruppel-like factor 11 and ischemic strokeR01NS086820 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YIN, KEJIE · 2015 to 2019
$1.7M
Long non-coding RNAs and cerebrovascular endothelial cell pathology in ischemic strokeR21NS094930 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YIN, KEJIE · 2015 to 2016
$425k
NINDS NIH HHS R01 NS075035NINDS NIH HHS R01 NS079153NINDS NIH HHS R01 NS086820NINDS NIH HHS R01 NS089901NINDS NIH HHS R01 NS091175NINDS NIH HHS R01 NS097000NINDS NIH HHS R01 NS101718NINDS NIH HHS R01 NS106950NINDS NIH HHS R21 NS094930
6 · The paper itself

Abstract

Central nervous system (CNS) injuries, such as stroke, traumatic brain injury (TBI) and spinal cord injury (SCI), are important causes of death and long-term disability worldwide. MicroRNA (miRNA), small non-coding RNA molecules that negatively regulate gene expression, can serve as diagnostic biomarkers and are emerging as novel therapeutic targets for CNS injuries. MiRNA-based therapeutics include miRNA mimics and inhibitors (antagomiRs) to respectively decrease and increase the expression of target genes. In this review, we summarize current miRNA-based therapeutic applications in stroke, TBI and SCI. Administration methods, time windows and dosage for effective delivery of miRNA-based drugs into CNS are discussed. The underlying mechanisms of miRNA-based therapeutics are reviewed including oxidative stress, inflammation, apoptosis, blood-brain barrier protection, angiogenesis and neurogenesis. Pharmacological agents that protect against CNS injuries by targeting specific miRNAs are presented along with the challenges and therapeutic potential of miRNA-based therapies.

Indexed as

AnimalsApoptosisBlood-Brain BarrierBrain Injuries, TraumaticDrug Delivery SystemsHumansInflammationMicroRNAsOxidative StressSpinal Cord InjuriesStrokeMicroRNAsmicroRNA inhibitorsMicroRNA mimicsspinal cord injurystroketraumatic brain injury

Identifiers

PMID29708005
PMCPMC6434449

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.